First Trust Advisors
BCLI

First Trust Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

First Trust Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,979
Closed -$284K – 2521
2021
Q2 		$284K Sell
4,979
-95
-2% -$5.08K ﹤0.01% 2377
2021
Q1 		$292K Buy
5,074
+950
+23% +$71.7K ﹤0.01% 2330
2020
Q4 		$280K Sell
4,124
-181
-4% -$24.6K ﹤0.01% 2231
2020
Q3 		$1.09M Buy
+4,305
New +$882K ﹤0.01% 1714

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Trust Advisors's BCLI Position: Q3 2021 in Review

First Trust Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2021, closing a stake of 4,979 shares — an estimated $284K sold.

First Trust Advisors first reported a position in BCLI in Q3 2020 and held it in 4 quarters. The position peaked at $1.09M in Q3 2020. 52 funds tracked by Wall St. Rank hold BCLI as of Q3 2021.

  • First Trust Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2021 after selling out during the quarter.
  • First Trust Advisors sold 4,979 BRAINSTORM CELL THERAPUTC shares in Q3 2021, an estimated $284K.
  • First Trust Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2020 and held it in 4 quarters.
  • First Trust Advisors's BRAINSTORM CELL THERAPUTC position peaked at $1.09M in Q3 2020.
  • 52 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2021.

Based on First Trust Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.